Skip to main content
Clinical Trials/IRCT20180301038906N1
IRCT20180301038906N1
Completed
Phase 3

Adjunctive Memantine Therapy for Negative Symptoms in Schizophrenia: A Double-Blind Placebo Controlled Study

Mashhad University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 3
Status
Completed
Enrollment
60

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • Schizophrenia in the relative recovery period
  • Use of atypical antipsychotics including risperidone and olanzapine
  • No other drugs (except anticholinergic and benzodiazepine)
  • Lack of pregnancy or breastfeeding
  • No serious organic disease and no drug use at the time of entering the study

Exclusion Criteria

  • There is serious organic disease
  • Pregnancy or breastfeeding
  • Existence of dementia

Investigators

Similar Trials